The growing field of targeted treatment relies heavily on recombinant mediator technology, and a precise understanding of individual profiles is essential for refining experimental design and therapeutic efficacy. Specifically, examining the properties of recombinant IL-1A, IL-1B, IL-2, and IL-3 demonstrates notable differences in their structure,